Cargando…
Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed to an intact bloodbrain barrier (BBB). We aim to develop a theoretical model including releva...
Autores principales: | El-Khouly, Fatma E., van Vuurden, Dannis G., Stroink, Thom, Hulleman, Esther, Kaspers, Gertjan J. L., Hendrikse, N. Harry, Veldhuijzen van Zanten, Sophie E. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670105/ https://www.ncbi.nlm.nih.gov/pubmed/29164054 http://dx.doi.org/10.3389/fonc.2017.00254 |
Ejemplares similares
-
DIPG-84. COMPLEMENTARY AND ALTERNATIVE MEDICINE IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma, et al.
Publicado: (2020) -
DIPG-33. CHARACTERIZING THE NEURO-VASCULAR UNIT IN DIFFUSE INTRINSIC PONTINE GLIOMA
por: El-Khouly, Fatma E, et al.
Publicado: (2020) -
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
por: El-Khouly, Fatma E., et al.
Publicado: (2021) -
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma
por: Bugiani, Marianna, et al.
Publicado: (2017) -
State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature
por: Veldhuijzen van Zanten, Sophie E. M., et al.
Publicado: (2016)